1
|
Alzahrani FA, Saadeldin IM, Ahmad A, Kumar D, Azhar EI, Siddiqui AJ, Kurdi B, Sajini A, Alrefaei AF, Jahan S. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients. Stem Cells Int 2020; 2020:8835986. [PMID: 33014070 PMCID: PMC7512102 DOI: 10.1155/2020/8835986] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/22/2020] [Accepted: 08/27/2020] [Indexed: 12/15/2022] Open
Abstract
A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease "COVID-19" and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells' sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients.
Collapse
Affiliation(s)
- Faisal A. Alzahrani
- Department of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Islam M. Saadeldin
- Department of Physiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, Egypt
- Department of Animal Production College of Food and Agriculture Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Abrar Ahmad
- Department of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Dipak Kumar
- Zoology Department, KKM College, Munger University, Jamui, India
| | - Esam I. Azhar
- Department of Medical Laboratories, College of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Arif Jamal Siddiqui
- Department of Biology, College of Science, University of Hail, Hail, Saudi Arabia
| | - Bassem Kurdi
- Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Abdulrahim Sajini
- Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, UAE
| | | | - Sadaf Jahan
- College of Applied Medical Science, Majmaah University, Al Majmaah, Saudi Arabia
| |
Collapse
|
2
|
Blanco S, Bandiera R, Popis M, Hussain S, Lombard P, Aleksic J, Sajini A, Tanna H, Cortés-Garrido R, Gkatza N, Dietmann S, Frye M. Stem cell function and stress response are controlled by protein synthesis. Nature 2016; 534:335-40. [PMID: 27306184 PMCID: PMC5040503 DOI: 10.1038/nature18282] [Citation(s) in RCA: 295] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Accepted: 04/21/2016] [Indexed: 12/18/2022]
Abstract
Whether protein synthesis and cellular stress response pathways interact to control stem cell function is currently unknown. Here we show that mouse skin stem cells synthesize less protein than their immediate progenitors in vivo, even when forced to proliferate. Our analyses reveal that activation of stress response pathways drives both a global reduction of protein synthesis and altered translational programmes that together promote stem cell functions and tumorigenesis. Mechanistically, we show that inhibition of post-transcriptional cytosine-5 methylation locks tumour-initiating cells in this distinct translational inhibition programme. Paradoxically, this inhibition renders stem cells hypersensitive to cytotoxic stress, as tumour regeneration after treatment with 5-fluorouracil is blocked. Thus, stem cells must revoke translation inhibition pathways to regenerate a tissue or tumour.
Collapse
Affiliation(s)
- Sandra Blanco
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Roberto Bandiera
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Martyna Popis
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Shobbir Hussain
- Department of Biology & Biochemistry, University of Bath,
Claverton Down, Bath BA2 7AY, United Kingdom
| | - Patrick Lombard
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Jelena Aleksic
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Abdulrahim Sajini
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Hinal Tanna
- University of Cambridge, CR-UK, Cambridge Institute, Li Ka Shing
Centre, Robinson Way, Cambridge CB2 0RE, UK
| | - Rosana Cortés-Garrido
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Nikoletta Gkatza
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Sabine Dietmann
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| | - Michaela Frye
- Wellcome Trust – Medical Research Council Cambridge Stem Cell
Institute, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, United
Kingdom
| |
Collapse
|
3
|
Greder LV, Gupta S, Li S, Abedin MJ, Sajini A, Segal Y, Slack JMW, Dutton JR. Analysis of endogenous Oct4 activation during induced pluripotent stem cell reprogramming using an inducible Oct4 lineage label. Stem Cells 2013; 30:2596-601. [PMID: 22948941 DOI: 10.1002/stem.1216] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The activation of endogenous Oct4 transcription is a key step in the reprogramming of somatic cells into induced pluripotent stem (iPS) cells but until now it has been difficult to analyze this critical event in the reprogramming process. We have generated a transgenic mouse that expresses the tamoxifen-inducible Cre recombinase MerCreMer under the control of the endogenous Oct4 locus, enabling lineage tracing of Oct4 expression in cells in vivo or in vitro, during either reprogramming or differentiation. Using this novel resource, we have determined the timing and outcome of endogenous Oct4 induction during fibroblast reprogramming. We show that both the initiation of this key reprogramming step and the ability of cells activating endogenous Oct4 expression to complete reprogramming are not influenced by the presence of exogenous c-Myc, although the overall efficiency of the process is increased by c-Myc. Oct4 lineage tracing reveals that new reprogramming events continue to initiate over a period of 3 weeks. Furthermore, the analysis of mixed colonies, where only a subset of daughter cells induce endogenous Oct4 expression, indicates the role of unknown, stochastic events in the progression of reprogramming from the initial events to a pluripotent state. Our transgenic mouse model and cells derived from it provide powerful and precise new tools for the study of iPS cell reprogramming mechanisms and have wider implications for the investigation of the role of Oct4 during development.
Collapse
Affiliation(s)
- Lucas V Greder
- Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | | | | | | | | | | | | | | |
Collapse
|